MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Restoring p53 activity by inhibiting the interaction between p53 and the mouse double minutes clone 2 (MDM2) offers an attractive approach to cancer therapy. Nutlin-3a is a small-molecule inhibitor that inhibits MDM2 binding to p53 and subsequent p53-dependent DNA damage signaling. In this study, we determined the efficacy of Nutlin-3a in inducing p53-mediated cell death in osteosarcoma (OS) cell lines both in vivo and in vitro. Targeted disruption of the p53-MDM2 interaction by Nutlin-3a stabilizes p53 and selectively activates the p53 pathway only in OS cells with wild-type p53, resulting in a pronounced anti-proliferative and cytotoxic effect due to G1 cell cycle arrest and apoptosis both in vitro and in vivo. p53 dependence of these alternative outcomes of Nutlin-3a treatment was shown by the abrogation of these effects when p53 was knocked-down by small interfering RNA. These data suggest that the disruption of p53-MDM2 interaction by Nutlin-3a might be beneficial for OS patients with MDM2 amplification and wt p53 status.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The IC50s reported in this study are consistent with previous reports showing that MDM2 amplified cancer cell lines (e.g. liposarcoma and osteosarcoma lines) are more sensitive to RG7112 or Nutlin-3 [25–28].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [27]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
mdm2 expression is induced by wild type p53 activity.
Barak, Y., Juven, T., Haffner, R., & Oren, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05678.x · Cited by 1,290
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
p53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Principles and Practice of Pediatric Oncology
Labotka, R. J. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540480082049 · Cited by 630
Dorfman, H. D., & Czerniak, B. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1+<203::aid-cncr2820751308>3.0.co;2-v · Cited by 496
Meyers, P. A., & Gorlick, R. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70540-x · Cited by 299
Current Treatment of Osteosarcoma
Ferguson, W. S., & Goorin, A. M. (2001) · Cancer Investigation · doi:10.1081/cnv-100102557 · Cited by 295
Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene
Chen, J., Lin, J., & Levine, A. J. (1995) · Molecular Medicine · doi:10.1007/bf03401562 · Cited by 213
Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII
Smeland, S., Müller, C., Alvegard, T. A., Wiklund, T., Wiebe, T., Björk, O., Stenwig, A. E., Willén, H., Holmström, T., Follerås, G., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00747-5 · Cited by 166
Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Van Maerken, T., Speleman, F., Vermeulen, J., Lambertz, I., De Clercq, S., De Smet, E., Yigit, N., Coppens, V., Philippé, J., De Paepe, A., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0792 · Cited by 159
Recent Advances in the Therapeutic Perspectives of Nutlin-3
Secchiero, P., Bosco, R., Celeghini, C., & Zauli, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222586 · Cited by 158
Inactivation of p53 gene in human and murine osteosarcoma cells
Chandar, N., Billig, B., McMaster, J. H., & Novak, J. F. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.43 · Cited by 157
Bacci, G., Longhi, A., Forni, C., Setola, E., & Ferrari, E. S. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00546-x · Cited by 155
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & G. Maki, C. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 147
p53: The Attractive Tumor Suppressor in the Cancer Research Field
Ozaki, T., & Nakagawara, A. (2011) · BioMed Research International · doi:10.1155/2011/603925 · Cited by 131
Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
Müller, C. R., Paulsen, E. B., Noordhuis, P., Pedeutour, F., Sæter, G., & Myklebost, O. (2007) · International Journal of Cancer · doi:10.1002/ijc.22643 · Cited by 119
Skin cancer. Melanoma and other specific nonmelanoma skin cancers
Elder, D. E. (1995) · Cancer · doi:10.1002/1097-0142(19950101)75:1+<295::aid-cncr2820751313>3.0.co;2-u · Cited by 107
Kitagawa, M., Aonuma, M., Lee, S. H., Fukutake, S., & McCormick, F. P. (2008) · Oncogene · doi:10.1038/onc.2008.164 · Cited by 91
Secchiero, P., di Iasio, M., Gonelli, A., & Zauli, G. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785294663 · Cited by 86
Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2
Cao, C., Shinohara, E. T., Subhawong, T. K., Geng, L., Woon Kim, K., Albert, J. M., Hallahan, D. E., & Lu, B. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0356 · Cited by 85
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Valentine, J. M., Kumar, S., & Moumen, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-79 · Cited by 77
Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma
Pishas, K. I., Al-Ejeh, F., Zinonos, I., Kumar, R., Evdokiou, A., Brown, M. P., Callen, D. F., & Neilsen, P. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1587 · Cited by 71
Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity
Bacci, G., Forni, C., Ferrari, S., Longhi, A., Bertoni, F., Mercuri, M., Donati, D. M., Capanna, R., Bernini, G., Briccoli, A., et al. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200311000-00006 · Cited by 70
Mechanism-specific signatures for small-molecule p53 activators
van Leeuwen, I. M. M., Higgins, M., Campbell, J., Brown, C. J., McCarthy, A. R., Pirrie, L., Westwood, N. J., & Laín, S. (2011) · Cell Cycle · doi:10.4161/cc.10.10.15519 · Cited by 52
Anticancer effects of the p53 activator nutlin-3 in Ewing’s sarcoma cells
Sonnemann, J., Palani, C. D., Wittig, S., Becker, S., Eichhorn, F., Voigt, A., & Beck, J. F. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.015 · Cited by 48
Antitumor effect of adenovirus-mediated p53 family gene transfer on osteosarcoma cell lines
Oshima, Y., Sasaki, Y., Negishi, H., Idogawa, M., Toyota, M., Yamashita, T., Wada, T., Nagoya, S., Satoshi, S., Yamashita, T., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.7.4320 · Cited by 42
Osteosarcoma Necrosis Following Chemotherapy: Innate Biology Versus Treatment-Specific
Gorlick, R. G., & Meyers, P. A. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200311000-00003 · Cited by 33
Zauli, G., Rimondi, E., Corallini, F., Fadda, R., Capitani, S., & Secchiero, P. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.070618 · Cited by 29
Research works printed but not linked: 1
- Rosen GF, Forscher CA, Mankin HJ, Selch MT, Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E. Neoplasm of bone and soft tissue. Cancer Medicine, 2000, 1870-1902.
Cited by
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
New targets and approaches in osteosarcoma
Gill, J., Ahluwalia, M. K., Geller, D., & Gorlick, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.09.003 · Cited by 273
Therapeutics targeting p53-MDM2 interaction to induce cancer cell death
Koo, N., Sharma, A. K., & Narayan, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095005 · Cited by 153
TP53 in bone and soft tissue sarcomas
Thoenen, E. A., Curl, A., & Iwakuma, T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.06.010 · Cited by 150
Metadata
- Authors
- Wang, B., Fang, L., Zhao, H., Xiang, T., & Wang, D.
- Affiliations
- Chinese People's Armed Police Force (CN)
- Chinese People's Armed Police General Hospital (CN)
- Qingdao University (CN)
- Venue
- Acta Biochimica et Biophysica Sinica
- Published
- 2012-08-01
- Volume
- 44
- Issue
- 8
- Pages
- 685-691
- ISSN
- 1672-9145 (ISSN-L)
- OpenAlex
- W2140723802
- Cited by
- 58
- References
- 33
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 4 · 2021: 8 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 7 · 2012: 1
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Biochimica et Biophysica Sinica (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- Nutlin-3a, MDM2 inhibitors, osteosarcoma, p53, p53-MDM2 interaction, apoptosis, cell proliferation, G1 cell cycle arrest, MDM2 amplification, small molecule inhibitors
- MeSH terms
- Animals, Cell Cycle, DNA Damage, Humans, Imidazoles, Neoplasm Transplantation, Piperazines, Osteosarcoma, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Mice, SCID, Apoptosis, RNA, Small Interfering, Cell Line, Tumor, Cell Proliferation, Mice, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.